See if TRYPTYR 0.003% helps dry eye symptoms and signs

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multicenter, prospective, open-label, single-arm study evaluating the effectiveness of acoltremon 0.003% (TRYPTYR) for dry eye disease. Participants will be followed at baseline, day 7, day 14, and day 28 with assessments including EDS-VAS, distance visual acuity, corneal fluorescein staining, conjunctival lissamine green staining, and the Pain Numerical Rating Scale. The study aims to observe changes in signs and symptoms over four weeks of treatment. Enrollment is limited to adults with a prior diagnosis of dry eye disease who meet specific clinical criteria and consent to participate.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Be able and willing to provide written informed consent and sign a Health Information Portability and Accountability Act (HIPAA) form prior to any study procedure being performed.
* Be able and willing to comply with the study requirements and attend all study visits.
* Be a minimum of 18 years of age of either sex and any race or ethnicity.
* Diagnosis of Dry Eye Disease at least 6 months before enrollment.
* Use of or desired use of artificial tears (AT), autologous serum or specific dry eye medications during the last 6 months prior to the selection phase.
* Symptoms reported on EDS-VAS \>= 40 \[0-100\].
* Total Corneal Fluorescein Staining of \>= 7 as assessed by the NEI scale \[0-15\].
* By subject report, not be pregnant or breastfeeding.

Exclusion Criteria:

* Be a female of childbearing potential who is currently pregnant, nursing, or planning a pregnancy.
* Have known contraindications or sensitivity to the use of any of the study medications or their components.
* Have an active ocular infection at Visit 1 (bacterial, viral, or fungal) in either eye, or evidence of ocular inflammation or symptomatic blepharitis, in the opinion of the investigator.
* In the opinion of the investigator, at Visit 1 have any clinically significant abnormal findings in either eye that would interfere with the interpretation of the study results or subject safety.
* Use of artificial tears 24 hours prior to screening, and any anticipated use throughout the study.
* Use of dry eye prescription medications 30 days prior to screening and throughout the study (includes autologous serum tears, cyclosporine, lifitegrast, varenicline nasal spray, steroids etc)
* Have previously used TRYPTYR (acoltremon 0.003%) ophthalmic solution in the past 6 months prior to screening
* Have less than or equal to +0.6 logarithmic minimum angle of resolution (logMAR) (approximately 20/80 Snellen) distance-corrected visual acuity (DCVA) in each eye at screening.
* Have completed participation in an investigational drug or drug study within 1 month of Visit 1.
* Have a condition or a situation, which, in the Investigator's opinion, may put the subject at increased risk, confound study data, or interfere significantly with the subject's study participation.
* Have had ocular surgical intervention (including laser procedures) of any kind within 6 months prior to Visit 1.
* Contact lens wear within 14 days of Visit 1 and unwilling to discontinue contact lens wear for the study duration.
* Use topical ocular medication of any kind (inclusive of LUMIFY®, LATISSE®, glaucoma medications) within 14 days of Visit 1 or throughout the study.
* Be unable to demonstrate proper eyedrop instillation (using a drop of saline from a vial, in office).
* The principal investigator reserves the right to declare a patient ineligible or non-evaluable based on medical evidence that indicates they are unsuitable for the trial.

Where it's running

• Doctor My Eyes
  Scottsdale, Arizona, United States Recruiting
• Scott & Christie and Associates, PC
  Cranberry Township, Pennsylvania, United States Recruiting

Study contacts

• Principal investigator: Natasha Hindman, OD — Scott & Christie and Associates, PC
• Study coordinator: Nichole Stadnik
• Email: nstadnik@scottandchristie.com
• Phone: 724-772-3000

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• BL1107 dosing for drying eye redness: finding the lowest effective amount

  This trial tests whether different doses of BL1107 can fully reduce conjunctival redness in people with dry eye disease, while keeping participants unaware of the dose they receive.

  Recruiting Phase 2 Bausch & Lomb Incorporated · Newport Beach, California · NCT07778888

• Eye drops from umbilical cord stem cell vesicles to help dry eye

  A tiny drop of human umbilical cord stem cell–derived vesicles is applied to the eye daily for four weeks to see if it helps dry eye symptoms and signs.

  Recruiting Early Phase 1 The First Affiliated Hospital of Xiamen University · Xiamen, China · NCT07623382

• Tear iron levels and dry eye severity

  This project will see if the amount of iron in tears is linked to how severe someone's dry eye is by comparing people with dry eye to healthy volunteers.

  Recruiting Shanghai Changzheng Hospital · Shanghai · NCT07363824

• Vitamin A–based eye ointment for dry, burning, or irritated eyes

  This trial will try a vitamin A–based ointment called Vit-A-Vision in adults with dry eye symptoms to see if it improves comfort and tear stability.

  Recruiting OmniVision GmbH · Cologne · NCT06596733

• Exploring dry eye disease patterns after cataract surgery

  This study looks at how cataract surgery affects dry eye symptoms in patients aged 50 to 90 and tests if using artificial tears helps improve their comfort over time.

  Recruiting Lithuanian University of Health Sciences · Kaunas · NCT06298890

• Comparing BUFY02 and TRB02 eye drops for dry eye disease

  This test will see if BUFY02 eye drops work as well as TRB02 eye drops to improve signs and symptoms for adults with dry eye disease when used daily for three months.

  Recruiting at 6 sites TRB Chemedica International SA · Graz and 5 other locations · NCT05865457

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.